Dec 31 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Axsome Therapeutics, Ducommun and Vacasa on Tuesday.
HIGHLIGHTS
* Axsome Therapeutics Inc AXSM.O: Needham raises target price to $133 from $130 |
* Ducommun Inc DCO.N: RBC reinstates coverage with outperform rating |
* Vacasa Inc VCSA.O: Needham cuts to hold from buy |
Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday. Stock entries are in alphabetical order.
* Axsome Therapeutics Inc AXSM.O: Needham raises target price to $133 from $130 |
* Axsome Therapeutics Inc AXSM.O: RBC raises target price to $138 from $132 |
* Cal-Maine Foods Inc CALM.O: Stephens raises target price to $88 from $82 |
* Ducommun Inc DCO.N: RBC reinstates coverage with outperform rating |
* Ducommun Inc DCO.N: RBC reinstates coverage with price target $72 vs $60 |
* Marinus Pharmaceuticals Inc MRNS.O: Baird raises target price to $0.55 from $0.50 |
* Vacasa Inc VCSA.O: Needham cuts to hold from buy |
* Verastem Inc VSTM.O: BTIG raises target price to $20 from $13 |
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。